CA2638794A1 - Formulation d'anticorps - Google Patents

Formulation d'anticorps Download PDF

Info

Publication number: CA2638794A1
Authority: CA; Canada
Prior art keywords: antigen; binding protein; binding; antibodies; domain
Prior art date: 2006-02-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002638794A

Other languages

English (en)

Inventor

Zhenping Zhu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ImClone LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-15

Filing date

2007-02-15

Publication date

2007-08-23

2007-02-15 Application filed by Individual filed Critical Individual

2007-08-23 Publication of CA2638794A1 publication Critical patent/CA2638794A1/fr

Status Abandoned legal-status Critical Current

Links

230000027455 binding Effects 0.000 claims abstract description 150
239000002246 antineoplastic agent Substances 0.000 claims abstract description 32
239000000427 antigen Substances 0.000 claims description 86
108091007433 antigens Proteins 0.000 claims description 86
102000036639 antigens Human genes 0.000 claims description 86
210000004027 cell Anatomy 0.000 claims description 74
102000005962 receptors Human genes 0.000 claims description 59
108020003175 receptors Proteins 0.000 claims description 59
238000000034 method Methods 0.000 claims description 51
102000025171 antigen binding proteins Human genes 0.000 claims description 43
108091000831 antigen binding proteins Proteins 0.000 claims description 43
239000003446 ligand Substances 0.000 claims description 34
108091008598 receptor tyrosine kinases Proteins 0.000 claims description 34
102000027426 receptor tyrosine kinases Human genes 0.000 claims description 34
108090000765 processed proteins & peptides Proteins 0.000 claims description 28
230000004913 activation Effects 0.000 claims description 26
102000004196 processed proteins & peptides Human genes 0.000 claims description 26
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 25
229920001184 polypeptide Polymers 0.000 claims description 24
230000014509 gene expression Effects 0.000 claims description 23
229940034982 antineoplastic agent Drugs 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 14
101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 12
230000000694 effects Effects 0.000 claims description 12
230000004614 tumor growth Effects 0.000 claims description 11
239000013604 expression vector Substances 0.000 claims description 10
230000033115 angiogenesis Effects 0.000 claims description 9
108020004414 DNA Proteins 0.000 claims description 8
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 7
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 7
230000019491 signal transduction Effects 0.000 claims description 7
-1 Tek Proteins 0.000 claims description 6
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 6
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 5
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 5
102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims description 5
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
230000003472 neutralizing effect Effects 0.000 claims description 5
108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims description 4
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
108091008794 FGF receptors Proteins 0.000 claims description 3
230000001580 bacterial effect Effects 0.000 claims description 3
210000004962 mammalian cell Anatomy 0.000 claims description 3
101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 2
101100481410 Mus musculus Tek gene Proteins 0.000 claims description 2
230000015572 biosynthetic process Effects 0.000 claims description 2
102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 2
101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 6
102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 6
101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 4
102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 4
108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 4
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 4
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 4
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 4
108020004511 Recombinant DNA Proteins 0.000 claims 2
230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 claims 1
101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 claims 1
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 claims 1
102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 1
210000005253 yeast cell Anatomy 0.000 claims 1
239000004037 angiogenesis inhibitor Substances 0.000 abstract description 4
230000001772 anti-angiogenic effect Effects 0.000 abstract description 3
229940041181 antineoplastic drug Drugs 0.000 abstract description 2
108090000623 proteins and genes Proteins 0.000 description 54
206010028980 Neoplasm Diseases 0.000 description 42
239000002773 nucleotide Substances 0.000 description 28
125000003729 nucleotide group Chemical group 0.000 description 28
102000004169 proteins and genes Human genes 0.000 description 27
230000000903 blocking effect Effects 0.000 description 26
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 23
150000001413 amino acids Chemical class 0.000 description 21
238000011282 treatment Methods 0.000 description 20
125000003275 alpha amino acid group Chemical group 0.000 description 18
238000002965 ELISA Methods 0.000 description 17
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 14
238000003556 assay Methods 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
108010017843 platelet-derived growth factor A Proteins 0.000 description 14
201000010099 disease Diseases 0.000 description 13
230000004927 fusion Effects 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
102000004584 Somatomedin Receptors Human genes 0.000 description 12
108010017622 Somatomedin Receptors Proteins 0.000 description 12
238000007792 addition Methods 0.000 description 12
239000000758 substrate Substances 0.000 description 12
101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 11
102100024952 Protein CBFA2T1 Human genes 0.000 description 11
201000011510 cancer Diseases 0.000 description 11
238000011534 incubation Methods 0.000 description 11
102000003992 Peroxidases Human genes 0.000 description 10
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
230000003993 interaction Effects 0.000 description 10
108040007629 peroxidase activity proteins Proteins 0.000 description 10
230000000638 stimulation Effects 0.000 description 10
108091008605 VEGF receptors Proteins 0.000 description 9
238000002835 absorbance Methods 0.000 description 9
230000026731 phosphorylation Effects 0.000 description 9
238000006366 phosphorylation reaction Methods 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
239000013598 vector Substances 0.000 description 9
201000004681 Psoriasis Diseases 0.000 description 8
238000001042 affinity chromatography Methods 0.000 description 8
238000004113 cell culture Methods 0.000 description 8
229940127089 cytotoxic agent Drugs 0.000 description 8
230000006870 function Effects 0.000 description 8
230000003463 hyperproliferative effect Effects 0.000 description 8
238000002823 phage display Methods 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 7
239000012634 fragment Substances 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
102000058223 human VEGFA Human genes 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000000159 protein binding assay Methods 0.000 description 6
238000012216 screening Methods 0.000 description 6
230000010474 transient expression Effects 0.000 description 6
101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
108060003951 Immunoglobulin Proteins 0.000 description 5
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 5
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000012292 cell migration Effects 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
102000018358 immunoglobulin Human genes 0.000 description 5
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
229960000485 methotrexate Drugs 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000005855 radiation Effects 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
102000014914 Carrier Proteins Human genes 0.000 description 4
102100024746 Dihydrofolate reductase Human genes 0.000 description 4
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
102000009465 Growth Factor Receptors Human genes 0.000 description 4
108010009202 Growth Factor Receptors Proteins 0.000 description 4
101710160107 Outer membrane protein A Proteins 0.000 description 4
108010003723 Single-Domain Antibodies Proteins 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
108091008324 binding proteins Proteins 0.000 description 4
238000010367 cloning Methods 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
108020001096 dihydrofolate reductase Proteins 0.000 description 4
230000009977 dual effect Effects 0.000 description 4
239000012636 effector Substances 0.000 description 4
229940126864 fibroblast growth factor Drugs 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
230000001613 neoplastic effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
108700005091 Immunoglobulin Genes Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241001529936 Murinae Species 0.000 description 3
102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010037575 Pustular psoriasis Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
101710120037 Toxin CcdB Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000006471 dimerization reaction Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
208000005017 glioblastoma Diseases 0.000 description 3
230000012010 growth Effects 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
210000001672 ovary Anatomy 0.000 description 3
239000000047 product Substances 0.000 description 3
210000002307 prostate Anatomy 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000009261 transgenic effect Effects 0.000 description 3
BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
102100023995 Beta-nerve growth factor Human genes 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
108010047041 Complementarity Determining Regions Proteins 0.000 description 2
101150029707 ERBB2 gene Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010015278 Erythrodermic psoriasis Diseases 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
241000724791 Filamentous phage Species 0.000 description 2
206010018338 Glioma Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
241000701024 Human betaherpesvirus 5 Species 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
101100372766 Mus musculus Kdr gene Proteins 0.000 description 2
108010025020 Nerve Growth Factor Proteins 0.000 description 2
108091008606 PDGF receptors Proteins 0.000 description 2
101150038994 PDGFRA gene Proteins 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
241000508269 Psidium Species 0.000 description 2
238000010240 RT-PCR analysis Methods 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
101150117115 V gene Proteins 0.000 description 2
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
238000011091 antibody purification Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000013357 binding ELISA Methods 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
231100000504 carcinogenesis Toxicity 0.000 description 2
230000003915 cell function Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940047120 colony stimulating factors Drugs 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
229960004679 doxorubicin Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000037433 frameshift Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
229940100602 interleukin-5 Drugs 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960004768 irinotecan Drugs 0.000 description 2
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
239000012528 membrane Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
230000010807 negative regulation of binding Effects 0.000 description 2
229940053128 nerve growth factor Drugs 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
229920002981 polyvinylidene fluoride Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
230000008685 targeting Effects 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940044693 topoisomerase inhibitor Drugs 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000001890 transfection Methods 0.000 description 2
101150108727 trpl gene Proteins 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
208000003200 Adenoma Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010032595 Antibody Binding Sites Proteins 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
241001429175 Colitis phage Species 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
102100031673 Corneodesmosin Human genes 0.000 description 1
101710139375 Corneodesmosin Proteins 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000003915 DNA Topoisomerases Human genes 0.000 description 1
108090000323 DNA Topoisomerases Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000588698 Erwinia Species 0.000 description 1
108091006020 Fc-tagged proteins Proteins 0.000 description 1
102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
201000010915 Glioblastoma multiforme Diseases 0.000 description 1
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100029571 Immunoglobulin J chain Human genes 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
101710196759 Macrophage-stimulating protein receptor Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101710204212 Neocarzinostatin Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000009608 Papillomavirus Infections Diseases 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
102100035194 Placenta growth factor Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
208000036822 Small cell carcinoma of the ovary Diseases 0.000 description 1
208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000011102 Thera Species 0.000 description 1
102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
201000001256 adenosarcoma Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940124691 antibody therapeutics Drugs 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
238000002725 brachytherapy Methods 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229930195731 calicheamicin Natural products 0.000 description 1
HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
229940127093 camptothecin Drugs 0.000 description 1
VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
229960005395 cetuximab Drugs 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229950006647 cixutumumab Drugs 0.000 description 1
238000012761 co-transfection Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000000032 diagnostic agent Substances 0.000 description 1
229940039227 diagnostic agent Drugs 0.000 description 1
238000010586 diagram Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
208000018554 digestive system carcinoma Diseases 0.000 description 1
AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229940082789 erbitux Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
229950009429 exatecan Drugs 0.000 description 1
ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
238000002710 external beam radiation therapy Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
230000009643 growth defect Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
201000002222 hemangioblastoma Diseases 0.000 description 1
238000005734 heterodimerization reaction Methods 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
102000054751 human RUNX1T1 Human genes 0.000 description 1
229950006359 icrucumab Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000005304 joining Methods 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000003471 mutagenic agent Substances 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
230000027405 negative regulation of phosphorylation Effects 0.000 description 1
QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
201000005292 ovarian small cell carcinoma Diseases 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
206010033898 parapsoriasis Diseases 0.000 description 1
101150050446 pelB gene Proteins 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
229940066779 peptones Drugs 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
201000010914 pustulosis of palm and sole Diseases 0.000 description 1
208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000003385 seborrheic keratosis Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000010187 selection method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
229950009268 zinostatin Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dermatology (AREA)
Oncology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Virology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

CA002638794A 2006-02-15 2007-02-15 Formulation d'anticorps Abandoned CA2638794A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US77399406P	2006-02-15	2006-02-15
US60/773,994		2006-02-15
PCT/US2007/004051 WO2007095338A2 (fr)	2006-02-15	2007-02-15	Formulation d'anticorps

Publications (1)

Publication Number	Publication Date
CA2638794A1 true CA2638794A1 (fr)	2007-08-23

Family

ID=38372140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002638794A Abandoned CA2638794A1 (fr)	2006-02-15	2007-02-15	Formulation d'anticorps

Country Status (11)

Country	Link
EP (1)	EP1986684A2 (fr)
JP (1)	JP2009526857A (fr)
KR (1)	KR20080106245A (fr)
CN (1)	CN101432015A (fr)
AU (1)	AU2007215013A1 (fr)
BR (1)	BRPI0707824A2 (fr)
CA (1)	CA2638794A1 (fr)
EA (1)	EA200870265A1 (fr)
MX (1)	MX2008010561A (fr)
NO (1)	NO20083785L (fr)
WO (1)	WO2007095338A2 (fr)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7871610B2 (en)	2003-08-12	2011-01-18	Dyax Corp.	Antibodies to Tie1 ectodomain
RU2423381C2 (ru)	2005-07-25	2011-07-10	Трабьон Фармасьютикалз, Инк.	Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
NZ612319A (en)	2006-06-12	2015-04-24	Emergent Product Dev Seattle	Single-chain multivalent binding proteins with effector function
ES2667729T3 (es)	2007-09-26	2018-05-14	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
US20090148905A1 (en)	2007-11-30	2009-06-11	Claire Ashman	Antigen-binding constructs
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
EP2365003A1 (fr)	2008-04-11	2011-09-14	Emergent Product Development Seattle, LLC	Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
EP2334705B1 (fr)	2008-09-26	2016-12-14	UCB Biopharma SPRL	Produits biologiques
WO2010079149A1 (fr) *	2009-01-09	2010-07-15	Ipk Gatersleben	Anticorps de fusion
EP2401298A1 (fr)	2009-02-24	2012-01-04	Glaxo Group Limited	Constructions de liaison d'antigène
WO2010097394A1 (fr)	2009-02-24	2010-09-02	Glaxo Group Limited	Constructions multivalentes et/ou multispécifiques de liaison au rankl
WO2010097386A1 (fr)	2009-02-24	2010-09-02	Glaxo Group Limited	Constructions de liaison d'antigène
EP2414391B1 (fr)	2009-04-02	2018-11-28	Roche Glycart AG	Anticorps multispécifiques renfermant des anticorps complets et des fragments fab monocaténaires
PT2417156E (pt)	2009-04-07	2015-04-29	Roche Glycart Ag	Anticorpos trivalentes, biespecíficos
JP2012527878A (ja) *	2009-05-28	2012-11-12	グラクソグループリミテッド	抗原結合タンパク質
US9676845B2 (en)	2009-06-16	2017-06-13	Hoffmann-La Roche, Inc.	Bispecific antigen binding proteins
NZ701769A (en)	2009-09-16	2016-06-24	Genentech Inc	Coiled coil and/or tether containing protein complexes and uses thereof
KR101108642B1 (ko) *	2009-09-29	2012-02-09	주식회사 녹십자	표피 성장 인자 수용체에 특이적으로 결합하는 항체
CN102958942A (zh) *	2009-12-29	2013-03-06	新兴产品开发西雅图有限公司	异二聚体结合蛋白及其应用
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
CN105524176B (zh) *	2010-05-21	2021-03-19	银溪制药股份有限公司	双特异性融合蛋白
CA2800173C (fr)	2010-05-21	2019-05-14	Ulrik Nielsen	Proteines hybrides bispecifiques
WO2012025530A1 (fr)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
CN103068847B (zh)	2010-08-24	2019-05-07	罗切格利卡特公司	可活化的双特异性抗体
JP6121904B2 (ja)	2010-09-08	2017-04-26	ハロザイムインコーポレイテッド	条件的活性治療用タンパク質を評価および同定する、または発展させる方法
KR20130121886A (ko)	2010-11-24	2013-11-06	글락소 그룹 리미티드	Ｈｇｆ를 표적으로 하는 다중특이적 항원 결합 단백질
WO2012085111A1 (fr)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
EP2658869B1 (fr) *	2010-12-30	2019-06-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Formats de liaison à l'antigène destinés à être utilisés dans des traitements thérapeutiques ou des dosages diagnostiques
CA2824824A1 (fr)	2011-02-28	2012-09-07	F. Hoffmann-La Roche Ag	Proteines monovalentes de liaison a l'antigene
MX341921B (es)	2011-02-28	2016-09-07	Hoffmann La Roche	Proteinas de union a antigeno.
AU2013207927B2 (en)	2012-01-10	2017-11-02	Biogen Ma Inc.	Enhancement of transport of therapeutic molecules across the blood brain barrier
RU2644341C2 (ru)	2012-02-10	2018-02-08	Дженентек, Инк.	Одноцепочечные антитела и другие гетеромультимеры
KR20150023889A (ko)	2012-06-27	2015-03-05	에프. 호프만-라 로슈 아게	2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도
CA2871882A1 (fr)	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Methode de fabrication de conjugues d'anticorps a region fc comprenant au moins une entite de liaison qui se lie specifiquement a une cible et leurs utilisations
CN110845618A (zh) *	2013-02-26	2020-02-28	罗切格利卡特公司	双特异性t细胞活化抗原结合分子
BR112016006929A2 (pt)	2013-10-11	2017-09-19	Hoffmann La Roche	Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
CR20160425A (es)	2014-03-14	2017-05-26	Novartis Ag	Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
EP3119423B1 (fr)	2014-03-15	2022-12-14	Novartis AG	Traitement du cancer avec un récepteur d'antigène chimérique
AU2015231155B2 (en) *	2014-03-21	2020-11-12	X-Body, Inc.	Bi-specific antigen-binding polypeptides
KR102355609B1 (ko)	2014-05-29	2022-01-27	마크로제닉스, 인크.	다중 암 항원에 특이적으로 결합하는 삼중-특이적 결합 분자 및 그것의 사용 방법
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
CA2955386A1 (fr)	2014-07-21	2016-01-28	Novartis Ag	Traitement du cancer au moyen d'un recepteur d'antigene chimerique anti-bcma humanise
JP6831777B2 (ja)	2014-07-21	2021-02-17	ノバルティスアーゲー	Ｃｄ３３キメラ抗原受容体を使用する癌の処置
EP3193915A1 (fr)	2014-07-21	2017-07-26	Novartis AG	Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
WO2016014553A1 (fr)	2014-07-21	2016-01-28	Novartis Ag	Récepteurs d'antigènes chimères synthétisés par l'intermédiaire d'une sortase
WO2016019300A1 (fr)	2014-07-31	2016-02-04	Novartis Ag	Sous-ensemble optimisé de lymphocytes t contenant un récepteur d'antigène chimère
US10851149B2 (en)	2014-08-14	2020-12-01	The Trustees Of The University Of Pennsylvania	Treatment of cancer using GFR α-4 chimeric antigen receptor
CN107108744B (zh)	2014-08-19	2020-09-25	诺华股份有限公司	抗cd123嵌合抗原受体(car)用于癌症治疗
DK3194443T3 (da)	2014-09-17	2021-09-27	Novartis Ag	Målretning af cytotoksiske celler med kimære receptorer i forbindelse med adoptiv immunterapi
ES2952717T3 (es)	2014-10-14	2023-11-03	Novartis Ag	Moléculas de anticuerpos contra PD-L1 y usos de las mismas
WO2016090034A2 (fr)	2014-12-03	2016-06-09	Novartis Ag	Méthodes de pré-conditionnement de cellules b dans une thérapie car
PL3227332T3 (pl)	2014-12-03	2020-06-15	F. Hoffmann-La Roche Ag	Wielospecyficzne przeciwciała
TWI746437B (zh)	2015-04-08	2021-11-21	瑞士商諾華公司	Ｃｄ２０療法、ｃｄ２２療法及與表現ｃｄ１９嵌合抗原受體（ｃａｒ）之細胞的組合療法
WO2016172583A1 (fr)	2015-04-23	2016-10-27	Novartis Ag	Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (fr)	2015-07-29	2017-02-02	Novartis Ag	Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
WO2017053469A2 (fr)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Polypeptides de liaison à cd3
CA3007671A1 (fr)	2015-12-17	2017-06-22	Novartis Ag	Molecules d'anticorps anti-pd-1 et leurs utilisations
WO2017106810A2 (fr)	2015-12-17	2017-06-22	Novartis Ag	Combinaison d'un inhibiteur de c-met avec une molécule d'anticorps dirigée contre pd-1 et ses utilisations
ES2847155T3 (es)	2016-01-21	2021-08-02	Novartis Ag	Moléculas multiespecíficas que fijan como objetivo CLL-1
JP2019513347A (ja)	2016-03-04	2019-05-30	ノバルティスアーゲー	複数のキメラ抗原受容体（ｃａｒ）分子を発現する細胞およびその使用
US11549099B2 (en)	2016-03-23	2023-01-10	Novartis Ag	Cell secreted minibodies and uses thereof
KR20180134385A (ko)	2016-04-15	2018-12-18	노파르티스 아게	선택적 단백질 발현을 위한 조성물 및 방법
WO2017210617A2 (fr)	2016-06-02	2017-12-07	Porter, David, L.	Régimes thérapeutiques pour cellules exprimant un récepteur antigénique chimérique (car)
JP7219376B2 (ja)	2016-07-15	2023-02-08	ノバルティスアーゲー	キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
WO2018023025A1 (fr)	2016-07-28	2018-02-01	Novartis Ag	Polythérapies de récepteurs d'antigènes chimériques adn inhibiteurs pd -1
MX2019001469A (es)	2016-08-01	2019-10-02	Novartis Ag	Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
TWI797091B (zh)	2016-10-07	2023-04-01	瑞士商諾華公司	利用嵌合抗原受體之癌症治療
AU2017356317A1 (en) *	2016-11-14	2019-05-30	Amgen Inc.	Bispecific or biparatopic antigen binding proteins and uses thereof
ES2912408T3 (es)	2017-01-26	2022-05-25	Novartis Ag	Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
US20200048359A1 (en)	2017-02-28	2020-02-13	Novartis Ag	Shp inhibitor compositions and uses for chimeric antigen receptor therapy
EP3615068A1 (fr)	2017-04-28	2020-03-04	Novartis AG	Agent ciblant le bcma et polythérapie incluant un inhibiteur de gamma-sécrétase
WO2018201056A1 (fr)	2017-04-28	2018-11-01	Novartis Ag	Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
CR20190593A (es)	2017-06-22	2020-05-10	Novartis Ag	Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
AU2018292618A1 (en)	2017-06-27	2019-12-19	Novartis Ag	Dosage regimens for anti-TIM-3 antibodies and uses thereof
MX2020000342A (es)	2017-07-11	2020-08-17	Compass Therapeutics Llc	Anticuerpos agonistas que se unen a cd137 humano y sus usos.
JP2020527572A (ja)	2017-07-20	2020-09-10	ノバルティスアーゲー	抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
WO2019089753A2 (fr)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Anticorps cd137 et antagonistes pd-1 et leurs utilisations
WO2019089798A1 (fr)	2017-10-31	2019-05-09	Novartis Ag	Compositions anti-car et procédés
AU2018368731A1 (en)	2017-11-16	2020-05-14	Novartis Ag	Combination therapies
EP3713961A2 (fr)	2017-11-20	2020-09-30	Compass Therapeutics LLC	Anticorps cd137 et anticorps ciblant un antigène tumoral et leurs utilisations
WO2019152660A1 (fr)	2018-01-31	2019-08-08	Novartis Ag	Polythérapie utilisant un récepteur antigénique chimérique
CN110305210B (zh) *	2018-03-27	2023-02-28	信达生物制药(苏州)有限公司	新型抗体分子、其制备方法及其用途
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3784351A1 (fr)	2018-04-27	2021-03-03	Novartis AG	Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
CN108610417B (zh) *	2018-04-28	2021-01-26	暨南大学	抗破伤风毒素中和抗体、其制备方法及用途
WO2019226658A1 (fr)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
EP3797120A1 (fr)	2018-05-21	2021-03-31	Compass Therapeutics LLC	Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk
US20210213063A1 (en)	2018-05-25	2021-07-15	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
US20210214459A1 (en)	2018-05-31	2021-07-15	Novartis Ag	Antibody molecules to cd73 and uses thereof
MX2020013443A (es)	2018-06-13	2021-02-26	Novartis Ag	Receptores de antigeno quimerico de bcma y usos de los mismos.
EP3810269A2 (fr)	2018-06-19	2021-04-28	Atarga, LLC	Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (fr)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Procédé de traitement de tumeurs neuroendocrines
GB2576914A (en) *	2018-09-06	2020-03-11	Kymab Ltd	Antigen-binding molecules comprising unpaired variable domains produced in mammals
KR20210107628A (ko)	2018-11-13	2021-09-01	콤파스 테라퓨틱스 엘엘씨	체크포인트 분자에 대한 다중특이적 결합 작제물 및 이의 용도
KR20210106484A (ko)	2018-12-20	2021-08-30	노파르티스 아게	Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도
EP3897637A1 (fr)	2018-12-20	2021-10-27	Novartis AG	Schéma posologique et combinaison pharmaceutique comprenant des dérivés de 3-(1-oxoisoindoline-2-yl) pipéridine-2,6-dione
US20220144807A1 (en)	2019-02-15	2022-05-12	Novartis Ag	3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113329792B (zh)	2019-02-15	2024-06-28	诺华股份有限公司	取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
US20220088075A1 (en)	2019-02-22	2022-03-24	The Trustees Of The University Of Pennsylvania	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
US20220185875A1 (en)	2019-03-18	2022-06-16	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific antibody specifically bound to vegf and ang2
US20220185876A1 (en)	2019-03-29	2022-06-16	Atarga, Llc	Anti fgf23 antibody
EP4048281A1 (fr)	2019-10-21	2022-08-31	Novartis AG	Polythérapies comprenant du vénétoclax et des inhibiteurs de tim-3
TW202128191A (zh)	2019-10-21	2021-08-01	瑞士商諾華公司	Tim-3抑制劑及其用途
CN114761037A (zh)	2019-11-26	2022-07-15	诺华股份有限公司	结合bcma和cd19的嵌合抗原受体及其用途
WO2021123902A1 (fr)	2019-12-20	2021-06-24	Novartis Ag	Combinaison d'anticorps anti-tim-3 mbg453 et d'anticorps anti-tgf-bêta nis793, avec ou sans décitabine ou l'anticorps anti pd-1 spartalizumab, pour le traitement de la myélofibrose et du syndrome myélodysplasique
AU2021207348A1 (en)	2020-01-17	2022-08-11	Novartis Ag	Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
EP4090762A1 (fr)	2020-01-17	2022-11-23	Becton, Dickinson and Company	Procédés et compositions pour sécrétomique unicellulaire
CN115397460A (zh)	2020-02-27	2022-11-25	诺华股份有限公司	制备表达嵌合抗原受体的细胞的方法
IL298262A (en)	2020-06-23	2023-01-01	Novartis Ag	A dosage regimen that includes derivatives of 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione
PE20231093A1 (es)	2020-07-16	2023-07-18	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
WO2022026592A2 (fr)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Molécules d'anticorps contre le coronavirus et leurs utilisations
JP2023536164A (ja)	2020-08-03	2023-08-23	ノバルティスアーゲー	ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
EP4204021A1 (fr)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Méthode de traitement de cancers exprimant le psma
EP4204020A1 (fr)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Méthode de traitement de cancers exprimant le psma
WO2022097065A2 (fr)	2020-11-06	2022-05-12	Novartis Ag	Variants fc d'anticorps
KR20230107617A (ko)	2020-11-13	2023-07-17	노파르티스 아게	키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
WO2022162569A1 (fr)	2021-01-29	2022-08-04	Novartis Ag	Régimes posologiques d'anticorps anti-cd73 et anti-entpd2 et leurs utilisations
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
WO2023044483A2 (fr)	2021-09-20	2023-03-23	Voyager Therapeutics, Inc.	Compositions et procédés pour le traitement du cancer positif her2
WO2023092004A1 (fr)	2021-11-17	2023-05-25	Voyager Therapeutics, Inc.	Compositions et méthodes pour le traitement de troubles liés à tau
TW202342548A (zh)	2022-02-07	2023-11-01	美商威特拉公司	抗獨特型(anti-idiotype)抗體分子及其用途
TW202400658A (zh)	2022-04-26	2024-01-01	瑞士商諾華公司	靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2023220695A2 (fr)	2022-05-13	2023-11-16	Voyager Therapeutics, Inc.	Compositions et procédés pour le traitement du cancer her2 positif
WO2024030976A2 (fr)	2022-08-03	2024-02-08	Voyager Therapeutics, Inc.	Compositions et procédés permettant le franchissement de la barrière hémato-encéphalique
WO2024168061A2 (fr)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Molécules d'anticorps se liant au sars-cov-2

2007
- 2007-02-15 CA CA002638794A patent/CA2638794A1/fr not_active Abandoned
- 2007-02-15 WO PCT/US2007/004051 patent/WO2007095338A2/fr active Application Filing
- 2007-02-15 CN CNA2007800111267A patent/CN101432015A/zh active Pending
- 2007-02-15 AU AU2007215013A patent/AU2007215013A1/en not_active Abandoned
- 2007-02-15 JP JP2008555359A patent/JP2009526857A/ja not_active Ceased
- 2007-02-15 EP EP07750859A patent/EP1986684A2/fr not_active Withdrawn
- 2007-02-15 KR KR1020087022202A patent/KR20080106245A/ko not_active Application Discontinuation
- 2007-02-15 EA EA200870265A patent/EA200870265A1/ru unknown
- 2007-02-15 BR BRPI0707824-2A patent/BRPI0707824A2/pt not_active Application Discontinuation
- 2007-02-15 MX MX2008010561A patent/MX2008010561A/es not_active Application Discontinuation
2008
- 2008-09-02 NO NO20083785A patent/NO20083785L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2007095338A2 (fr)	2007-08-23
JP2009526857A (ja)	2009-07-23
EA200870265A1 (ru)	2009-02-27
EP1986684A2 (fr)	2008-11-05
NO20083785L (no)	2008-11-17
WO2007095338A3 (fr)	2008-04-17
KR20080106245A (ko)	2008-12-04
BRPI0707824A2 (pt)	2011-05-10
CN101432015A (zh)	2009-05-13
AU2007215013A1 (en)	2007-08-23
MX2008010561A (es)	2009-03-02

Publication	Publication Date	Title
CA2638794A1 (fr)	2007-08-23	Formulation d'anticorps
JP2008512352A (ja)	2008-04-24	新規な四価の二重特異性抗体
US20040259156A1 (en)	2004-12-23	Bispecific immunoglobulin-like antigen binding proteins and method of production
CN113260379B (zh)	2022-09-02	蛋白酶可切割的双特异性抗体及其用途
US20090028859A1 (en)	2009-01-29	Bispecific antibodies that bind to vegf receptors
JP2024504471A (ja)	2024-01-31	Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
KR20230074192A (ko)	2023-05-26	인간 cd3 엡실론에 결합하는 신규의 인간 항체
IL299232A (en)	2023-02-01	Bispecific antibody and its use
TW202202530A (zh)	2022-01-16	具有H2L2與HCAb結構的結合蛋白
WO2004003211A1 (fr)	2004-01-08	Anticorps bispecifiques qui se lient aux recepteurs de vegf
KR102357951B1 (ko)	2022-02-07	프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도
KR20230018397A (ko)	2023-02-07	다중 특이적 항체
US20230051266A1 (en)	2023-02-16	Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
JP2024527020A (ja)	2024-07-19	抗原結合分子の組合せ
CA3228682A1 (fr)	2023-02-23	Anticorps anti-b7-h4, son procede de preparation et son utilisation
EA046716B1 (ru)	2024-04-15	Биспецифические антитела к bcma/4-1bb и пути их применения

Legal Events

Date	Code	Title	Description
2008-08-12	EEER	Examination request
2011-02-15	FZDE	Discontinued